Cassie Homer

By Cassie Homer, Senior Managing Editor Save to PDF April 12, 2022 By <em>By Cassie Homer, Senior Managing Editor</em> The FDA granted HPN328, a delta like ligand 3 (DLL3) targeting therapy, orphan drug designation for the treatment of patients with small cell lung cancer, according to a press release from the manufacturer. The manufacturer used its Tri-specific T cell Activating Construct (TriTAC) platform to develop the drug.

Receive an email when new articles are posted on this topic . Please provide your email address to receive an email when new articles are posted on this topic . About 25% of genetic variants of uncertain significance detected in testing for hereditary cancer risk were later reclassified as benign or pathogenic, according to a retrospective study that assessed 10 years of data from a single institution.

PHOENIX — If implemented in community cancer centers, the telehealth program Project ECHO could impact patients and providers by bringing education and best practices to rural communities, according to a presentation at the Association of Community Cancer Centers National Oncology Conference. Project ECHO brings together centers of excellence and primary care clinicians via a telehealth model to educate, share cases and exponentially grow health care specialists across a variety of programs.